

University of Warwick institutional repository: <http://go.warwick.ac.uk/wrap>

This paper is made available online in accordance with publisher policies. Please scroll down to view the document itself. Please refer to the repository record for this item and our policy information available from the repository home page for further information.

To see the final version of this paper please visit the publisher's website. Access to the published version may require a subscription.

Author(s): Ladds G, Wright M H, Farquhar M J, Aletrari M O, Hodgkin M N

Article Title: Identification of caspase 3 motifs and critical aspartate residues in human Phospholipase D1b and Phospholipase D2a

Year of publication: 2008

Link to published version: <http://dx.doi.org/10.1016/j.bbrc.2008.02.064>

Identification of caspase 3 motifs and critical aspartate residues in human
Phospholipase D1b and Phospholipase D2a.

Michelle H Wright, Michelle J Farquhar, Mina-olga Aletrari, Graham Ladds and
Matthew N Hodgkin

Department of Biological Sciences, University of Warwick, Coventry West Midlands
CV4 7AL United Kingdom

Keywords: human, phospholipase D, caspase, apoptosis.

ABSTRACT

Stimulation of mammalian cells frequently initiates phospholipase D-catalysed hydrolysis of phosphatidylcholine in the plasma membrane to yield phosphatidic acid (PA) a novel lipid messenger. PA plays a regulatory role in important cellular processes such as secretion, cellular shape change and movement. A number of studies have highlighted that PLD-based signalling also plays a pro-mitogenic and pro-survival role in cells and therefore anti-apoptotic. We show that human PLD1b and PLD2a contain functional caspase-3 cleavage sites and identify the critical aspartate residues within PLD1b that affect its activation by phorbol esters and attenuate phosphatidylcholine hydrolysis during apoptosis.

1. INTRODUCTION

In mammalian cells, many agonists stimulate concurrent activation of phospholipase C (PLC), phospholipase A₂ (PLA₂) phosphatidylinositol 3-kinase and phospholipase D (PLD)-catalysed hydrolysis of phosphatidylcholine (PtdCho) to yield the novel lipid messenger phosphatidic acid (PA) [1-3]. In human cells, PLD1b and PLD2a are the most commonly expressed variants; both contain the characteristic HKD catalytic triad (the 'PLD domain') characteristic of members of the PLD-superfamily and have similar domain structures [1,2,4]. The role of ADP-ribosylation factors (Arfs), the Rho-family of proteins, protein kinase C (PKC) and polyphosphoinositides in regulating phospholipase D activity and localisation is now largely understood [1,2, 5-7].

PLD-catalysed PtdCho hydrolysis plays a regulatory role in important processes such as the oxidative burst in neutrophils [8,9], secretion [10-12], mitogenesis [13,14] and cellular shape change and adhesion [15-17]. Changes in the dynamics of the actin cytoskeleton may represent the common target for PLD signalling for at least some of these processes [15]. We have recently shown a functional link between role and regulation of PLD1b through association with F-actin during antigen-induced secretion in RBL-2H3 cells [17].

Apoptosis is a highly regulated pathway for cellular execution, initiated by changes in the balance of pro-mitogenic/differentiation signals versus pro-death signals [3, 18,19] that is characterised by membrane blebbing, phosphatidylserine exposure, cytosolic shrinkage, mitochondrial and nuclear disruption[18,19]. Apoptotic cell death is implemented following auto-activation of a class of cysteine proteases (caspases), which specifically cleave protein targets containing appropriate aspartate residue within consensus motifs [19,20]. Ligation of cell-surface death receptors leads

to recruitment of adaptor proteins and subsequent activation of caspase-8 that converts inactive caspases-3 and -7 to the active forms, which execute the apoptotic program [18-22]. Known caspase substrates include cell adhesion molecules (e.g. Cadherins), cytoskeletal proteins (e.g. actin and gelsolin), nuclear proteins (lamins), cell-cycle proteins (cyclin A/E), DNA metabolising enzymes (PARP), transcription factors (NF- κ B) and signal transduction proteins including receptors, adaptors, kinases, phosphatases and PLA₂ [21,22].

In some cells phosphatidylcholine hydrolysis has been reported to increase during apoptosis [23-25], whereas in others PLD activity has been reported to decrease [26-28]. Furthermore, inhibiting PLD activity can initiate apoptosis [29,30] with over-expression of PLD1 or PLD2 protecting various cancerous cells from apoptosis [31-34], possibly via mechanisms that stabilises p53 via activation of mTOR [35,36] and/or Raf1 or Ral [33]. Thus PLD-based signalling is most likely to be pro-survival and anti-apoptotic [1-3, 25-35]. It is possible that PLD represents a legitimate target for the apoptotic machinery to enable plasma membrane remodelling [2] and necessary disruption of the cytoskeleton. Recently, PLD1 signalling has been shown to be anti-apoptotic in calphostin-c treated smooth muscle cells and inhibition of PLD activity by calphostin-c promoted inhibition of microtubule reorganisation [37]. Here we show that human PLD1b and PLD2a contain functional caspase-3 cleavage sites and identify the critical aspartate residues within PLD1b that affect its activation by phorbol esters and attenuate phosphatidylcholine hydrolysis during apoptosis.

2. MATERIAL AND METHODS

Bioinformatic analysis of phospholipase sequences.

Sequences for human PLD1 (accession number **Q13393-2**) and PLD2 (accession number **O14939**), rodent phospholipases D, phospholipase C and phospholipase A2 were analysed using the Predictor of Protease Specificity (PoPS) web-based bioinformatics tool from Monash University (<http://pops.csse.monash.edu.au/>). PoPS provides an arithmetic score for detected sites based on the consensus sequences for the selected protease. Five residues are used by the program to score a caspase-3 site within a sequence; these are the 4 residues N-terminal of the cleaved peptide bond (S1-S4) and the first C-terminal residue (S1'). An ideal caspase site would score 25 and weak sites can be filtered from the report using a selected threshold, which was specified at 15 in this study. Results from the PoPS were compared to motif searching within the phospholipase D sequences using 4 residue caspase sites with the consensus sequence of DXXD or D/E, D/E, X, D [20].

Generation of vectors expressing GFP-PLD mutants

The open reading frames (ORF) for human PLD1b or PLD2a were cloned in to pcDNA3.1 with an N-terminal GFP tag. Regions from PLD1b or PLD2a were sub-cloned in to pBluescript using convenient restriction sites and specified aspartate codons changed to alanine by site-directed PCR mutagenesis. The sub-cloned fragments were re-inserted in to the appropriate human PLD ORF in pcDNA3.1. The presence of the mutation within the reconstructed ORF was confirmed by sequencing.

Digestion of *in vitro*-produced PLD proteins by Caspase 3

2µg plasmid mini-prep DNA (pcDNA3.1 harbouring GFP-PLD1b/PLD2a or mutants; predicted molecular weights of 148kDa and 134kDa respectively) was incubated with coupled *in vitro* transcription and translation reagent (Promega) and 100µCi [³⁵S]-methionine (90 minutes at 30°C). Produced PLD proteins were incubated with 25nM caspase-3 (Biomol) in assay buffer (50mM HEPES pH7.4, 100mM NaCl, 0.1% CHAPS, 1mM EDTA, 10% glycerol, 10mM DTT). The competitive inhibitor Acetyl-DDVD-Cho (Pharmingen) was incubated with caspase for 15 minutes prior to mixing with substrates. Proteins were separated by SDS-PAGE (4-12% Tris-glycine gels) and stained with coomassie blue dye. Dried gels were exposed to a storage phosphor screen (Molecular Probes) for 90 minutes before visualisation and quantification of radioactivity (Total-Lab v1). Radioactivity per band was plotted as a percentage of total radioactivity per lane (units). Recombinant PLD1b was produced as described [6,17], digested with caspase 3 (as above) and fragments identified by western blotting using the specified antibodies.

Cell culture and transfection

HEK-293 cells, grown in Dulbecco's modified eagles medium (DMEM) with pyruvate and glutamax (Invitrogen), plus foetal calf serum (10%v/v), penicillin (100U) and streptomycin (100mg/ml) at 37°C in humidified 5% CO₂ and passaged at 90% confluency. Two hours prior to transfection growth media was substituted for DMEM without additions. Transfection complexes were prepared in DMEM (without additions) by complexing 6µg DNA with 6µl Plus™ reagent for 15 minutes followed by 5µl of Lipofectamine (Invitrogen) in a final volume of 100µl and incubated with cells for 4 hours before media was replaced with supplemented DMEM. Where necessary cells were grown on coated cover-slips, washed in phosphate-buffered

saline, fixed in paraformaldehyde and visualised using a Leica con-focal microscope at 488nm.

Measurement of phospholipase D activity

HEK-293 cells, transfected as described, were quiesced and labelled with 2 μ Ci/ml [³H] palmitic acid overnight (0.1%BSA, 0.1M HEPES pH7.4), washed twice with 0.1%BSA, 0.1M HEPES, pH7.4 and incubated with 0.3% butan-1-ol for 15 minutes. Cells were stimulated with phorbol ester (PMA) for 30 minutes and lipids extracted with ice-cold methanol, chloroform and water. The lipid phase was dried under N₂ gas and re-suspended in chloroform prior to separation by thin layer chromatography (TLC) developed in chloroform:methanol:acetone:acetic acid and phosphatidylbutanol (PtdBut) was visualised in iodine vapour scraped and counted (expressed as percentage of total lipid labelling).

3. RESULTS

Searches of the protein sequences of human PLD1b and PLD2a with two consensus motifs for caspase 3 cleavage (DXXD or D/E, D/E, X, D) [20] identified several putative sites. The Predictor of Protease Specificity (PoPS) web-based bioinformatics tool provided quantitative scores for the putative caspase cleavage sites within PLD sequences. Within PoPS, caspase 3 sites are defined using four residues N-terminal (S4-S1) and one residue C-terminal (S1') to the cleaved peptide bond to give a maximum achievable score of 25. PoPS analysis identified 3 putative caspase-3 sites (with scores above 15) in the protein sequence of human PLD1b and 2 putative sites in human PLD2a (Figure 1A). All of these sites had been identified using the consensus sequence approach.

In human PLD1b, two of the putative caspase sites are located in the 'loop region' at DDVD₅₄₉S and DFID₆₃₁R between the PLD domains (Figure 1B). The remaining caspase 3 site in the N-terminus of PLD1b at EEVD₄₁Y, is known to be the region of PKC interaction and phosphorylation sites (Figure 1B) [17]. Two high-scoring putative caspase-3 sites were also identified in the N-terminus of human PLD2a (Figure 1A) at DELD₁₆S and DEVD₂₈T. Of the 3 caspase sites identified in human PLD1b, DFID₆₆₉R is conserved in the rat, but not the mouse, PLD1 sequence. Of the 2 caspase-3 sites found in human PLD2a, DEVD₂₈T is conserved within the mouse but not rat PLD2 sequences. Analysis of the sequences of phospholipases C (β , γ , δ) and various phospholipase A2 variants demonstrated that the occurrence of these putative caspase 3 sites is specific to phospholipases D (results not shown).

To determine if PLD1b was a caspase-3 substrate, purified recombinant and catalytically active [6,17] GST-PLD1b (1 μ g) was incubated with purified recombinant caspase-3 (100ng) at 37°C for 0-60 minutes and PLD1b fragments

separated by SDS-PAGE and detected by western blotting with commercial antibodies against an internal PLD1b sequence (Biosource; PLD1b residues 523-540) and the C-terminus (Santa Cruz). Figure 1C shows that human recombinant PLD1b is rapidly (within 10 minutes) cleaved by caspase-3 into two fragments; one of 75-90kDa (F1) recognised by the internal antibody and one of 50-60kDa (F2) recognised by the C-terminal antibody. The sizes of the produced fragments were consistent with cleavage of GST-hPLD1b at one of the two centrally placed putative caspase-3 sites, rather than D₄₁. PLD1b degradation was inhibited by pre-incubating caspase-3 with the competitive peptide inhibitor Ac-DEVD-Cho [22], but not prevented by inclusion of excess free glutathione S-transferase. The larger PLD1b fragment (75-90kDa) was also identified by antibodies raised against the N-terminal of PLD1b (Biosource) and by an anti-GST (Sigma; results not shown), suggesting that it consisted of at least residues 1-540 of PLD1b and the intact GST tag. GST-hPLD1b remained caspase-3 sensitive at caspase to PLD1b ratios of 1:25 and 1:100 (results not shown).

To identify which aspartate residues were responsible for directing caspase-mediated cleavage of PLD1b, D₄₁, D₅₄₅ and D₆₃₁ were mutated to alanine and proteins expressed by coupled *in vitro* transcription and translation in the presence of ³⁵S-methionine. Labelled PLD1b proteins were incubated with caspase-3 and fragments separated by SDS-PAGE prior to identification and quantification by phosphorimage analysis. Figure 2A shows that wild type GFP-PLD1b is successfully expressed *in vitro* and is rapidly degraded by caspase-3 to two fragments; one of 75-90kDa (F1) and one of approximately 50kDa (F2). Mutation of D₅₄₅ to alanine renders PLD1b insensitive to caspase-mediated cleavage whereas mutation of D₆₃₁ does not prevent cleavage. Cleavage is specific to caspase-3 since pre-incubation of caspase 3 with the peptide competitive inhibitor (Ac-DEVD-Cho) prevents PLD1b degradation.

Mutation of D₄₁ to alanine did not prevent cleavage of PLD1b (results not shown). Figure 2b shows quantification of radioactivity within the 148kDa parent GFP-hPLD1b (wild-type and mutants) band following incubation with caspase-3 from 3 separate experiments. As a control human GFP-hPLD2a (134kDa) was also expressed using *in vitro* coupled transcription and translation. Mutation of D₁₆, but not D₂₈, to alanine renders human PLD2a caspase-3 insensitive (Fig. 2C and 2D). Figure 3A shows that approximately half of the *in vitro* produced GFP-PLD1b protein (at 148kDa) is degraded by caspase-3 within 10 minutes with a concomitant increase in radioactivity in the 70-80kDa fragment (F1). Degradation of GFP-PLD1b is dependent on caspase-3 concentration with near maximal levels of degradation occurring at 15-20nM caspase 3 (Fig. 3B).

GFP, GFP-PLD1b or GFP-PLD1b_{D545A} and GFP-PLD1b_{D631A} were successfully expressed by transient transfection of human embryonic kidney cells (HEK-293) as determined by con-focal microscopy. Figure 4A shows that GFP is more weakly expressed than wild type PLD1b or the PLD1b mutants. Phorbol ester-stimulated PLD activation was measured in HEK 293 cells expressing GFP alone. The results in figure 4B show that increasing concentrations of phorbol ester result in a 4-fold increase in PLD activity as determined by formation of phosphatidylbutanol. Transfection of HEK-293 with GFP-PLD1b wt or PLD1b mutants resulted in an approximate 3-fold increase in basal activity that was statistically significant. However, only wild type-GFP-PLD1b and GFP-PLD1b_{D545A} showed phorbol ester sensitive increases in PLD activity following transfection, mutation of D₆₃₁ to alanine rendered this mutant insensitive to subsequent phorbol ester mediated stimulation.

HEK-293 cells expressing wild-type GFP-PLD1b were initiated in to apoptosis by UV-light treatment and phorbol ester-stimulated phosphatidylcholine

hydrolysis was measured over 24 hours. During this period there was a 4-fold increase in caspase activity (results not shown) and at 24 hours the cells showed a significant amount of apoptotic phenotypes including membrane blebbing and nuclear condensation and fragmentation (results not shown). In cells expressing wild-type PLD1b, PMA-stimulated phosphatidylcholine hydrolysis initially declined after UV treatment but was followed by a sustained rise in PtdBut accumulation between 4-12 hours (Fig. 4C). Whilst the initial decline in phosphatidylcholine hydrolysis was also apparent in apoptosing cells expressing hPLD1b_{D545A}, much of the second sustained phase of phosphatidylcholine hydrolysis observed between 4 and 12 hours was lost (Fig. 4C). This data suggests that over-expression of a caspase-resistant form of PLD1b reduces the progress of phosphatidylcholine hydrolysis in apoptosing cells.

4. DISCUSSION

Both human PLD1b and PLD2a contain previously unrecognised caspase 3 cleavage sites not present in rat or mouse phospholipases D. In PLD2a, the caspase 3 site is located in the N-terminus at residue D₁₆ whereas in hPLD1b, the caspase 3 cleavage site is located in the loop region between the HKD motifs at residue D₅₄₉. The caspase motif identified in PLD1b (DEVD₅₄₅S) is similar the classical caspase site identified in DNA topoisomerase I (DEVD) cytosolic PLA2 (DELD) and cleavage at this site is inhibited by the known peptide competitor DDVD [22,38,39]. Structure and functional analysis has shown that PLD1b activity can be reconstituted when the ORF is separated (genetically) within the loop region and the two halves co-expressed within cells [40]. This observation has led to the suggestion that interaction of the HKD motifs in the PLD domains, via folding of the loop region, is necessary for catalytic activity [1,40]. Our data suggests that caspase-mediated cleavage of PLD1b could provide a post-translational mechanism that mimics this observation.

Whilst mutation of D₅₄₉ to alanine in PLD1b did not affect phorbol ester activation of PLD1b in HEK 293 cells, mutation of D₆₃₁ to alanine prevented stimulation of phosphatidylcholine hydrolysis. This data suggests that within the loop region D₆₃₁ plays a role in regulating activation of PLD1b. Since the PKC binding and phosphorylation sites within PLD1b and located in the extreme N-terminus [17], the mechanism by which this mutation prevents phosphatidylcholine hydrolysis is not clear.

Expression of the caspase-3 resistant form of PLD1b reduced the extent of UV-initiated phosphatidylcholine hydrolysis in HEK 293 cells undergoing apoptosis. Apoptosis involves a complex interplay of irreversible changes to the plasma-

membrane, cytoskeleton and nucleus and our data suggest that PLD activity may either be targeted for destruction to facilitate these changes or through caspase-mediated degradation become deregulated and therefore able to play a role in facilitating apoptotic changes.

Acknowledgments

MHW and MJF were funded by the BBSRC.

References

1. McDermott M, Wakelam MJO, and Morris AJ (2004). *Phospholipase D*. *Biochemical and Cell Biology* **82**, pp225-253.
2. Cazzolli R, Shemon AN, Fang MQ, Hughes WE (2006). *Phospholipid signalling through phospholipase D and phosphatidic acid*. *Life* **58**(8), pp457-461.
3. Nozawa Y (2002). *Role of Phospholipase D in apoptosis and pro-survival*. *Biochimica et Biophysica Acta* **1585**, pp77-86.
4. Ponting CP and Kerr ID (1996). *A novel family of phospholipase d homologues that includes phospholipid synthases and putative endonucleases: Identification of duplicated repeats and potential active sites*. *Protein Science* **5**, pp914-922.
5. Hodgkin MN, Masson MR, Powner D, Saqib KM, Ponting CP and Wakelam MJO (2000). *Phospholipase D regulation and localisation is dependent upon a phosphatidylinositol 4,5-bisphosphate-specific PH domain*. *Current Biology* **10**, pp43-46
6. Powner D, Hodgkin MN and Wakelam MJO (2002). *Antigen stimulated activation of phospholipase D1b by Rac1, Arf6 and PKC α in RBL-2H3 cells*. *Molecular Biology of the Cell* **13**, pp1252-1262
7. Du G, Altshuler YA, Vitale N, Huang P, Chasserot-Golaz S, Morris AJ, Bader M-F and Frohman MA (2003). *Regulation of phospholipase d1 subcellular cycling through coordination of multiple membrane association motifs*. *The Journal of Cell Biology* **162**, pp305-315
8. Palicz A, Foubert TR, Jesaitis AJ, Marodi L and McPhail LC (2001). *Phosphatidic acid and diacylglycerol directly activate NADPH oxidase by interacting with enzyme components*. *Journal of Biological Chemistry* **276**, pp3090-3097
9. Kusner DJ, Barton JA, Qin C, Wang X and Iyer SS (2003). *Evolutionary conservation of physical and functional interactions between phospholipase D and actin*. *Archives of Biochemistry and Biophysics* **412**, pp231-241.
10. Brown FD, Thompson N, Saqib KM, Clark JM, Powner D, Thompson NT, Solari R and Wakelam MJO (2001). *Phospholipase D1 localises to secretory granules and lysosomes and is plasma-membrane translocated on cellular stimulation*. *Current Biology* **8**, pp835-838
11. O'Lunaigh N, Pardo R, Fensome A, Allen-Baume V, Jones D, Holt MR and Cockcroft S (2002). *Continual production of phosphatidic acid by phospholipase D is essential for antigen-stimulated membrane ruffling in cultured mast cells*. *Molecular Biology of the Cell* **13**, pp3730-3746
12. Zeniou-Meyer M, Zabari N, Ashery U, Chasserot-Golaz S, Haeberlé AM, Demais V, Bailly Y, Gottfried I, Nakanishi H, Neiman AM, Du G, Frohman MA, Bader MF and Vitale N (2007). *Phospholipase D1 production of phosphatidic acid at the plasma membrane promotes exocytosis of large dense-core granules at a late stage*. *Journal of Biological Chemistry* **282**, pp21746-57.

- 13 Zhao C, Du G, Skowronek K, Frohman MA and Bar-Sagi D (2006) *Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras by SoS*. Nature Cell Biology **9**, pp706-712
- 14 Rozengurt E (2007) *Mitogenic signalling pathways induced by G-protein coupled receptors*. Journal of Cellular Physiology in press.
- 15 Cross MJ, Roberts S, Ridley AJ, Hodgkin MN, Stewart A, Claesson-Welsh L and Wakelam MJ (1996) *Stimulation of actin stress fibre formation mediated by activation of phospholipase D*. Current Biology **6**, pp588-597
- 16 Powner DJ, Pettit TR, Anderson R, Nash GB, and Wakelam MJO (2007). *Stable adhesion of human neutrophils requires phospholipase D-mediated activation of the integrin CD11b/CD18*. Molecular Immunology **44**, pp3211-3221.
- 17 Farquhar MJ, Powner DJ, Levine BA, Wright MH, Ladds G and Hodgkin MN (2007). *Interaction of PLD1b with actin in antigen-stimulated mast cells*. Cellular Signalling **19**, pp349-358.
18. Guimaraes CA and Linden R (2004). *Programmed cell death: apoptosis and alternative death styles*. European Journal of Biochemistry **271**, pp1638-1650.
19. Degtarev A, Boyce M and Yuan J (2003). *A decade of Caspases*. Oncogene **22**, pp8543-8567
20. Earnshaw WC, Martins LM and Kaufmann SH (1999). *Mammalian caspases: structure, activation, substrates and functions during apoptosis*. Annual Review in Biochemistry **68**, pp383-424
21. Fisher U, Janicke RU and Schulze-Osthoff K (2003). *Many cuts to ruin: a comprehensive review of caspase substrates*. Cell Death and Differentiation **10**, pp76-100
22. Timmer JC and Slavesson GS (2007) *Caspase Substrates*. Cell Death and Differentiation **14**, pp66-72
23. Ahn S-J, Yoon M-S, Hyuk S, Han W, Yoon Y-D, Han J-S and Noh D-Y. (2002). *Phospholipase C-protein kinase c mediated phospholipase D activation pathway is involved in tamoxifen-induced apoptosis*. Journal of Cellular Biochemistry **89**, pp520-528
24. Kasai T, Ohguchi K, Nakashima S, Ito Y, Naganawa T, Kondo N and Nozawa Y (1998). *Increased activity of oleate-dependent type phospholipase D during actinomycin D-induced apoptosis in Jurkat T cells*. The Journal of Immunology **161**, pp6469-6474
25. Lim SY, Lee S-C, Shin I and Han J-S (2002). *Differential effects of Fas cross-linking on phospholipase D activation and related lipid metabolism in Fas-resistant A20 cells*. Experimental and Molecular Medicine **34**, pp201-210

26. Nakashima S and Nozawa Y (1999). *Possible role of phospholipase D in cellular differentiation and apoptosis*. Chemistry and Physics of Lipids **98**, pp153-164
27. Iwasaki-Bessho Y, Banno Y, Yoshimura S, Ito Y, Kitajima Y and Nozawa Y (1998). *Decreased phospholipase D activity in ceramide-induced apoptosis of human keratinocyte cell line HaCaT*. Journal of Investigative Dermatology **110**, 376-382
28. Chen JS, Chai MQ, Chen HH, Zhao S and Song JG (2000). *Regulation of phospholipase D activity and ceramide production in daunorubicin-induced apoptosis in A-431 cells*. Biochimica et Biophysica Acta **1488**, pp219-232
29. Park M-A, Lee M-J, Lee S-H, Jung D-K and Kwak J-Y (2002). *Anti-apoptotic role of phospholipase D in spontaneous and delayed apoptosis of human neutrophils*. FEBS letters **519**, pp45-49
30. Zhong M, Shen Y, Zheng Y, Joseph T, Jackson D and Foster DA (2003). *Phospholipase D prevents apoptosis in v-Src transformed fibroblasts and MDA MB 231 breast cancer cells*. Biochemical and Biophysical Research Communications **302**, pp615-619
31. Yamada M, Banno Y, Takuma Y, Koda M, Hara A and Nozawa Y (2004). *Overexpression of phospholipase D prevents actinomycin D-induced apoptosis through potentiation of phosphoinositide 3-kinase signalling pathways in chinese hamster ovary cells*. Biochemical Journal **378**, pp649-656.
32. Oh KJ, Lee SC, Choi HJ, Oh DY, Kim SC, Min do S, Kim JM, Lee KS and Han JS (2007). *Role of phospholipase D2 in anti-apoptotic signaling through increased expressions of Bcl-2 and Bcl-xL*. Journal Cellular Biochemistry. **101**, pp1409-22.
33. Shi M, Zheng Y, Garcia A Xu L and Foster DA (2007) *Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras*. Cancer Letters **258**, pp268-275
34. Cho JH, Hong SK, Kim EY, Park SY, Park CH, Kim JM, Kwon OJ, Kwon SJ, Lee KS and Han JS (2007). *Overexpression of phospholipase D suppresses taxotere-induced cell death in stomach cancer cells*. Biochim Biophys Acta. in press.
35. Hui L, Abbas T, Pielak RM, Joseph T, Bargonetti J and Foster DA (2004). *Phospholipase D elevates the level of MDM2 and suppresses DNA damage induced increases in p53*. Molecular and Cellular Biology **24**, pp5677-5686
36. Avila-Flores A, Santos T, Rincon E and Merida I (2005). *Modulation of mammalian target of rapamycin pathway by diacylglycerol kinase –produced phosphatidic acid*. Journal of Biological Chemistry **280**, pp10091-10099
37. Zheng XL, Gui Y, Du G, Frohman MA and Peng DQ (2004). *Calphostin-C induction of vascular smooth muscle cell apoptosis proceeds through phospholipase D and microtubule inhibition*. Journal of Biological Chemistry **279**, pp7112-7118

38. Samejima K, Svingen PA, Basi GS, Kottke T, Mesner PW Jr, Stewart L, Durrieu F, Poirier GG, Alnemri ES, Champoux JJ, Kaufmann SH and Earnshaw WC (1999). *Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis*. Journal of Biological Chemistry. **274**, pp4335-40.
39. Wissing D, Mouritzen H, Egeblad M, Poirier GG and Jäättelä M (1997). *Involvement of caspase-dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced apoptosis*. Proceedings of National Academy Science (USA). **94**, pp5073-5077.
40. Xie Z, Ho W-T and Exton JH (1998). *Association of N-and C-terminal domains of phospholipase D1 is required for its catalytic activity*. Journal of Biological Chemistry **273**, pp34679-34682

LEGENDS

Figure 1. Human PLD is a potential caspase-3 substrate.

(A) Putative caspase-3 cleavage sites in human PLD1b and PLD2a were identified and scored (out of 25) using PoPS. (B) Purified recombinant GST-PLD1b (1 μ g) was incubated with caspase 3 (100ng) for up to 60 minutes with or without Ac-DEVD-Cho inhibitor (2 μ M) or excess recombinant GST (xsr-GST - 2.5 μ g) and fragments separated by SDS-PAGE (4-12%) prior to identification by western blotting with hPLD1 specific antibodies raised to an internal sequence (Biosource) or the C-terminal of PLD1b (Santa Cruz) and ECL. (C) A schematic representation of the human PLD1b sequence showing the positions of PX, PH and PLD domains, putative caspase-3 cleavages sites and antibody epitopes.

Figure 2. Identification of caspase-3 motifs PLD1b and PLD2a

Wild-type and mutated forms of human GFP-PLD1b (A) and GFP-PLD2a (B) were expressed *in vitro* in the presence of ³⁵S-methionine. Produced proteins were incubated at 37°C for 60 minutes with caspase-3 with or without pre-incubation with peptide inhibitor and labelled fragments (F1 and F2 for PLD1b and F3 and F4 for PLD2a) separated by SDS-PAGE prior to visualisation and quantification by phosphorimaging (results for PLD1b-panel C, PLD2a -panel D). Images are representative of 3 experiments and bars charts show mean radioactivity remaining in the parent PLD band (1b/2a) as a % of total, +/- SEM. Luciferase (61kDa) expression was a control for the coupled transcription and translation process.

Figure 3. Caspase 3 catalysed cleavage of PLD1b is both time and dose – dependent.

Wild type human GFP-PLD1b was expressed *in vitro* as described. (A) Produced PLD1b protein was incubated at 37°C for up to 120 minutes with caspase 3 (25nM). (B) Produced PLD1b protein was incubated at 37°C for 120 minutes with caspase 3 (0-50nM). Labelled fragments were separated and quantified as before. Graphs show mean radioactivity remaining in the parent PLD1b band (148kDa) in the 70-90kDa (F1) band as a % of total, +/- SEM from 3 experiments.



Figure 4. Expression of a caspase-3 resistant PLD1b in HEK-293 cells.


HEK 293 cells transiently expressing GFP, GFP-hPLD1b, D_{545A} or D_{631A} were fixed and GFP-fluorescence localised by confocal microscopy (panel A). Similarly transfected (GFP, GFP-hPLD1b-wild type, D_{545A} or D_{631A}) HEK-293 cells were labelled ³H-palmitate prior to stimulation with phorbol ester (0-300nM) in the presence of butan-1-ol (0.3%w/v). Accumulated phosphatidylbutanol (PtdBut) was separated by thin layer chromatography, extracted and quantified by scintillation counting. Results in panel B are means from triplicate determinations +/- SEM. HEK-293 cells transiently transfected with pcDNA3.1 expressing GFP-hPLD1b or GFP-hPLD1bD_{545A} and labelled with ³H-palmitate prior to initiation in to apoptosis by UV-light treatment. PMA-stimulated (300nM) phosphatidylbutanol accumulation was quantified over 24 hours (panel C) as means from triplicate determinations +/- SEM.

Figure



A

| hPLD1b Sequence | PoPS Score | hPLD2a sequence | PoPS Score |
|-----------------------|------------|----------------------|------------|
| EEVD ₄₁ Y | 16.8 | DELD ₁₆ S | 20 |
| DDVD ₅₄₉ S | 21.2 | DEVD ₂₈ T | 22 |
| DFID ₆₆₉ R | 15.3 | | |





Figure



Figure

